Board Member

Dr. STEFANO MILLERI
Board Member, CRC Verona S.r.l.

Dr. Stefano Milleri has extensive and well-established experience in clinical research. He served as Head of the Clinical Pharmacology Unit at the Glaxo Research Centre from 1992 to 2002 and subsequently became Director of the Clinical Pharmacology and Experimental Medicine Unit at the same GlaxoSmithKline centre starting in 2002.

From 2006 to 2016, he was Scientific Director of Centro Ricerche Cliniche di Verona S.r.l., and from 2016 to 2025 he served as Medical Scientific Director and, on an interim basis, Head of the Operations Unit.
In his role at CRC, Dr. Milleri coordinated all the centre's activities, leading a team of approximately 40 professionals, including physicians, nurses, pharmacists, and administrative staff, all carefully selected and highly qualified. The team is currently involved in around 140 studies at different stages of research, including Phase I trials.

His objective has been to ensure adherence to the highest clinical, ethical, and quality standards in clinical research, while guaranteeing full integration with the various operational units of the G.B. Rossi University Hospital in Verona, where CRC is located. This integration enabled the conduct of clinical studies meeting the efficiency requirements of sponsors, including leading global pharmaceutical companies.
Dr. Milleri has overseen more than 70 studies (mainly in respiratory diseases, vaccines, and healthy volunteers) as Principal Investigator and has participated in more than 150 studies as Co-Investigator across various therapeutic areas, including Oncology, Hematology, Neurology, and CNS disorders.

He is an adjunct professor in the Specialization Program in Clinical Pharmacology and Toxicology at the University of Florence and a lecturer in numerous master's programs at several Italian universities, including Verona and Pisa. He is co-author of more than 100 publications, including articles and posters, as well as regulatory dossiers submitted to the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA).